ACLY is necessary for tumorigenesis in mouse models of cancer, and the tool compound inhibitors of ACLY with high IC50 values have been reported to have anti-tumor efficacy in xenograft models of lung and prostate cancer [59]. Here, ACLY is linked to prostate carcinoma.